3 Key Takeaways
- Participants who received a booster dose of Ad26.ZEBOV either 1 year or 2 years after the initial vaccination exhibited a comparable and robust humoral immune response. This indicates that the timing for booster administration can be flexible, allowing for tailored vaccination schedules that could accommodate varying levels of Ebola virus exposure risk among populations.
- GMCs of Ebola virus glycoprotein-specific IgG binding antibodies saw an approximately 39-fold increase from pre-booster levels just 7 days after administrating the booster dose.
- The study also highlights the vaccine and booster's safety profile, they were well-tolerated among participants, with the most common adverse events being injection site pain or tenderness and headaches.
This open-label, single-center, randomized, phase 2 study was at a single hospital in Boende, Democratic Republic of the Congo. It involved adult healthcare providers and frontline workers, with individuals having a history of Ebola virus disease excluded. Participants received a 2-dose, different-component vaccine schedule, with injections 56 days apart. The first dose was Ad26.ZEBOV and the second MVA-BN-Filo, each administered as a 0.5 mL intramuscular shot in the deltoid muscle.
“We assessed serious adverse events occurring up to 6 months after the last dose and local and systemic solicited and unsolicited adverse events reported for 7 days after the booster vaccination,” according to investigators. “Antibody responses were analyzed per protocol, serious adverse events per FAS, and adverse events for all boosted FAS participants.”
319 participants in group 1 and 317 in group 2 received booster doses. Dropout rates were 8% in group 1 and 7% in group 2, mainly due to loss to follow-up or relocation. The most reported adverse events were injection site pain or tenderness (27% in group 1 and 28% in group 2) and headaches (29% in both groups), which were related to the vaccine. There was 1 serious adverse event reported in group 2, where a participant developed a fever of ≥40.0°C following the booster.
This study faced limitations, enrolling 700 participants within 3 years as part of a 4-year project made it hard to schedule a blood collection for group 2 a year after their booster shot. This made it difficult to compare long-term antibody persistence between the 2 groups post-booster. Assessing neutralizing anti-Ebola virus antibodies due to budget constraints for a large participant group. Studies in non-human primates informed the decision to focus on binding antibodies, which indicated a significant link between binding antibody levels and survival.
The study showed that the vaccine and booster dose were well tolerated, with Ebola virus glycoprotein binding antibodies lasting up to 2 years after the initial vaccine. The findings support considering the Ad26.ZEBOV booster for individuals at risk of Ebola, such as healthcare providers, up to two years after the primary vaccine.
Reference
1. Larvière Y, Matuvanga T, Osang’ir B, Milolo S, et. al. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomized, phase 2 trial. The Lancet. Published March 26, 2024. Accessed March 27, 2024. doi: https://doi.org/10.1016/S1473-3099(24)00058-6